Diquafosol
From Wikipedia, the free encyclopedia
(Redirected from INS-365)
![]() |
|
Names | |
---|---|
IUPAC name
[[[[(2R,3S,4R,5R)-5-(2,4-Dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
|
|
Other names
P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium
|
|
Identifiers | |
59985-21-6 ![]() 211427-08-6 (tetrasodium salt) ![]() |
|
3D model (Jmol) | Interactive image |
ChEMBL | ChEMBL1767408 ChEMBL221326 |
ChemSpider | 130647 130646 (tetrasodium salt) |
1736 | |
PubChem | 148197 148196 (tetrasodium salt) |
UNII | 7828VC80FJ |
|
|
|
|
Properties | |
C18H26N4O23P4 | |
Molar mass | 790.31 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010.[1] It is formulated as a 3% ophthalmic solution of the tetrasodium salt.
Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.[2]
References[edit]
- ^ "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan". April 16, 2010.
- ^ Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters. 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.